To include your compound in the COVID-19 Resource Center, submit it here.

ChemoCentryx reports OS data for CCR2 antagonist in pancreatic cancer

ChemoCentryx Inc. (NASDAQ:CCXI) said CCX872 plus FOLFIRINOX chemotherapy led to an 18-month overall survival rate

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE